Michelle L Apperson, MD
Neurology · Sacramento
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
- Since medical school
- 25 years
- University of Hawaii John A. Burns School of Medicine, 2001
On the public record
- 1 Medical Board action on record
Offices
5 locations · Regents of the Univ of CA · 1,571 clinicians in this group
Hospitals listed: Adventist Health Sonora · University of California Davis Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Apperson’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A82317 · Current
Licensed to practise in California · since 2003 · expires 2028-09-30 · University of Hawaii School of Medicine. Board flags: Public Reprimand.
Public record actions
| 2021-03-11 | Board disciplineDiscipline | Public letter of reprimand. · 8002018051112 |
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Neurology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health SonoraSonora, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 64% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Postoperative wound dehiscence rate: 3.5 (2.04 to 4.96) · 288 cases, Jul 2022 – Jun 2024Worse than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 1.3 (1 to 1.6) · 1,004 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.185, Oct 2024 – Sep 2025
- University of California Davis Medical CenterSacramento, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UC Davis Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 1.94 (1.18 to 2.71) · 3,010 cases, Jul 2022 – Jun 2024Worse than the national rate — MRSA Bacteremia: 1.564, Oct 2024 – Sep 2025Worse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.7 (5.6 to 8) · 1,134 cases, Jan 2024 – Dec 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.6 (10.9 to 14.5) · 1,134 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 127.46 (95.81 to 159.1) · 281 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.18 (0 to 0.57) · 12,625 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.677, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.713, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,436 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Adventist Health Sonora
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 1 better, 7 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative wound dehiscence rateComplications and deaths | 3.5 (2.04 to 4.96) · 288 cases | Worse | Jul 2022 – Jun 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (1 to 1.6) · 1,004 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.185 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.15 (0.14 to 2.16) · 582 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.5 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 182.91 (123.44 to 242.37) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 118 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9 · 125 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.7 · 236 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15 · 433 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12 · 72 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,364 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.39) · 3,671 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.07 to 0.48) · 3,602 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.24 to 5.59) · 803 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.24) · 310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.59 (0.98 to 4.2) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.97 (0 to 16.16) · 306 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.72 (1.85 to 9.58) · 277 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 1.06) · 2,750 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.614 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 105 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 209 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 12.6 · 119 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -23.8 · 255 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13.4 · 455 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 381 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6 (4.3 to 8.1) · 328 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.7 (9.1 to 14.7) · 328 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 106 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.3) · 1,835 cases | No different | Jan 2022 – Dec 2024 |
What patients said (326 patients answered, 21% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 93% |
See every measure and the patient survey for University of California Davis Medical Center
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 1 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.94 (1.18 to 2.71) · 3,010 cases | Worse | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 1.564 | Worse | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.6 to 8) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (10.9 to 14.5) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 127.46 (95.81 to 159.1) · 281 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.57) · 12,625 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.677 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.713 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,436 cases | Better | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.78 to 1.19) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.2 · 115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 662 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 406 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 4,328 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,828 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.13 to 0.46) · 14,152 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.29 (2.92 to 5.66) · 4,920 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.78 (0.46 to 3.09) · 2,250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (1.06 to 3.09) · 4,696 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.46 (5.18 to 13.75) · 2,102 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.35 (3.74 to 8.96) · 2,191 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.48 (1.19 to 3.77) · 1,169 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.826 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.669 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 131 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 751 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -25.8 · 127 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.1 · 758 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.6 · 477 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.3 · 203 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.4 to 14.9) · 2,643 cases | No different | Jan 2022 – Dec 2024 |
What patients said (2,768 patients answered, 18% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 61% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$47,990
Medicare paid this office $47,990 for 297 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 169 | $25,814 | $106 |
| Return visit (30+ min) | 128 | $10,293 | $72 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 198 | $3,564 | $13 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 47 | $2,388 | $24 |
| Short return visit (20+ min) | 21 | $1,116 | $47 |
Who their Medicare patients are
297 Original Medicare patients in 2024. Average age 63 · Under 65 46% · Women 74% · Also on Medicaid 48% · Health risk score 1.82. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 56% · Depression 35% · Diabetes 23% · Coronary heart disease 15% · COPD 13% · Chronic kidney disease 11% · Cancer 10% · Atrial fibrillation 10% · Dementia 10% · Stroke 10% · Heart failure 9%.
The office billed $303,216, Medicare allowed $64,857 and paid $47,990; for 842 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 297 | 842 | 63 | 1.82 | $303,216 | $47,990 |
| 2023 | 296 | 517 | 64 | 1.64 | $258,753 | $42,337 |
| 2022 | 281 | 500 | 62 | 1.64 | $245,450 | $39,213 |
| 2021 | 281 | 516 | 61 | 1.72 | $246,938 | $45,440 |
| 2020 | 294 | 509 | 60 | 1.80 | $169,259 | $33,649 |
| 2019 | 357 | 525 | 61 | 1.85 | $229,037 | $41,224 |
| 2018 | 286 | 458 | 59 | 1.79 | $202,780 | $34,920 |
| 2017 | 290 | 460 | 60 | 1.57 | $208,811 | $36,280 |
| 2016 | 248 | 418 | 59 | 1.78 | $148,575 | $26,434 |
| 2015 | 162 | 241 | 61 | 1.75 | $78,399 | $16,279 |
| 2014 | 124 | 175 | 61 | 1.49 | $45,949 | $12,120 |
| 2013 | 110 | 159 | 59 | 1.66 | $42,821 | $11,497 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Long return visit (40+ min) | 146 | $19,147 | $108 |
| Return visit (30+ min) | 93 | $7,266 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $3,464 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $2,832 | $66 |
| New patient visit (60+ min) | 12 | $1,654 | $138 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,475 | $105 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 35 | $1,406 | $24 |
| Short return visit (20+ min) | 24 | $1,186 | $49 |
2022: 4 services
| Long return visit (40+ min) | 139 | $19,547 | $102 |
| Return visit (30+ min) | 115 | $9,734 | $73 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 29 | $1,871 | $26 |
| Short return visit (20+ min) | 18 | $853 | $45 |
2021: 6 services
| Long return visit (40+ min) | 184 | $29,597 | $109 |
| Return visit (30+ min) | 95 | $7,205 | $67 |
| New patient visit (60+ min) | 18 | $2,142 | $119 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $1,421 | $57 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 24 | $923 | $26 |
| Short return visit (20+ min) | 15 | $735 | $49 |
2020: 5 services
| Long return visit (40+ min) | 124 | $11,565 | $73 |
| Return visit (30+ min) | 120 | $7,980 | $56 |
| Telephone medical discussion with physician, 21-30 minutes | 90 | $6,709 | $63 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $1,168 | $40 |
| Short return visit (20+ min) | 14 | $562 | $40 |
2019: 5 services
| Long return visit (40+ min) | 209 | $23,965 | $80 |
| Return visit (30+ min) | 87 | $5,638 | $54 |
| New patient visit (60+ min) | 33 | $4,114 | $125 |
| New patient visit (45+ min) | 12 | $1,171 | $98 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $833 | $76 |
2018: 3 services
| Long return visit (40+ min) | 209 | $25,238 | $77 |
| Return visit (30+ min) | 64 | $3,702 | $51 |
| New patient visit (60+ min) | 23 | $3,037 | $132 |
2017: 4 services
| Long return visit (40+ min) | 191 | $21,125 | $77 |
| New patient visit (60+ min) | 42 | $4,993 | $119 |
| Return visit (30+ min) | 68 | $4,426 | $55 |
| New patient visit (45+ min) | 25 | $2,505 | $100 |
2016: 5 services
| Return visit (30+ min) | 151 | $9,533 | $49 |
| Return visit (30+ min) | 85 | $5,432 | $62 |
| Long return visit (40+ min) | 32 | $2,792 | $85 |
| Long return visit (40+ min) | 14 | $1,141 | $76 |
| Short return visit (20+ min) | 14 | $456 | $33 |
2015: 5 services
| Return visit (30+ min) | 107 | $8,831 | $59 |
| New patient visit (60+ min) | 11 | $1,505 | $137 |
| Long return visit (40+ min) | 13 | $1,177 | $91 |
| New patient visit (45+ min) | 12 | $1,158 | $97 |
| Short return visit (20+ min) | 23 | $813 | $35 |
2014: 2 services
| Return visit (30+ min) | 76 | $5,777 | $56 |
| Short return visit (20+ min) | 14 | $578 | $41 |
2013: 3 services
| Return visit (30+ min) | 68 | $5,233 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,896 | $158 |
| Long return visit (40+ min) | 11 | $863 | $78 |
Medicaid work
$6,958 in 2024
Medicaid paid $6,958 for 117 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 104 | $6,216 |
| Return visit (30+ min) | 13 | $741 |
| 2024 | 117 | 2 | 20 | $6,958 |
| 2023 | 30 | 1 | 15 | $2,777 |
| 2022 | 18 | 1 | 18 | $1,712 |
| 2021 | 114 | 1 | 17 | $9,246 |
| 2020 | 114 | 3 | 19 | $6,172 |
| 2019 | 131 | 2 | 19 | $7,594 |
| 2018 | 159 | 2 | 20 | $8,003 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 30 | $2,777 |
2022
| Long return visit (40+ min) | 18 | $1,712 |
2021
| Long return visit (40+ min) | 114 | $9,246 |
2020
| Long return visit (40+ min) | 62 | $3,479 |
| Return visit (30+ min) | 39 | $2,520 |
| Hospital outpatient clinic visit for assessment and management of a patient | 13 | $172 |
2019
| Long return visit (40+ min) | 101 | $7,594 |
| Hospital outpatient clinic visit for assessment and management of a patient | 30 | $0 |
2018
| Long return visit (40+ min) | 87 | $7,886 |
| Hospital outpatient clinic visit for assessment and management of a patient | 72 | $117 |
Drugs they prescribed that Part D paid
$7,684,413
Pharmacies billed $7,684,413 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (14 of 2,214) in 2024. Above the middle of the specialty; the typical neurology clinician is at 0%.
1,588 generic and fewer than 11 brand-name prescriptions · $7,684,413 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Kesimpta | None | 120 | $1,724,639 | $14,372 |
| Gilenya | None | 36 | $858,256 | $23,840 |
| Tecfidera | None | 59 | $744,925 | $12,626 |
| Vumerity | None | 73 | $654,941 | $8,972 |
| Gammagard Liquid | Immune globulin | 52 | $550,239 | $10,582 |
See all 42 drugs
| Kesimpta | None | 120 | $1,724,639 | $14,372 |
| Gilenya | None | 36 | $858,256 | $23,840 |
| Tecfidera | None | 59 | $744,925 | $12,626 |
| Vumerity | None | 73 | $654,941 | $8,972 |
| Gammagard Liquid | Immune globulin | 52 | $550,239 | $10,582 |
| Copaxone | None | 55 | $522,326 | $9,497 |
| Mayzent | None | 23 | $433,971 | $18,868 |
| Bafiertam | None | 23 | $221,537 | $9,632 |
| Aubagio | None | 13 | $214,604 | $16,508 |
| Glatiramer Acetate | None | 84 | $211,021 | $2,512 |
| Fingolimod | None | 142 | $193,720 | $1,364 |
| Hizentra | Immune globulin | 26 | $131,598 | $5,061 |
| Ampyra | None | 17 | $118,890 | $6,994 |
| Glatopa | None | 24 | $110,505 | $4,604 |
| Dimethyl | None | 38 | $109,825 | $2,890 |
| Dalfampridine Er | None | 139 | $89,035 | $641 |
| Teriflunomide | None | 61 | $43,031 | $705 |
| Modafinil | None | 108 | $6,438 | $60 |
| Baclofen | None | 167 | $6,281 | $38 |
| Levetiracetam | None | 47 | $4,401 | $94 |
| Mycophenolate Mofetil | None | 33 | $4,293 | $130 |
| Gabapentin | None | 114 | $3,765 | $33 |
| Lacosamide | None | 25 | $2,350 | $94 |
| Pregabalin | None | 53 | $2,064 | $39 |
| Carbamazepine | None | 15 | $1,210 | $81 |
| Dextroamphetamine-Amphet Er | None | 25 | $1,174 | $47 |
| Tizanidine | None | 41 | $1,042 | $25 |
| Amitriptyline | None | 19 | $802 | $42 |
| Duloxetine | None | 27 | $774 | $29 |
| Topiramate | None | 25 | $646 | $26 |
| Valacyclovir | None | 16 | $470 | $29 |
| Dextroamphetamine-Amphetamine | None | 15 | $373 | $25 |
| Diazepam | None | 39 | $335 | $9 |
| Sumatriptan | None | 16 | $266 | $17 |
| Carbidopa-Levodopa | None | 13 | $258 | $20 |
| Oxybutynin Chloride | None | 15 | $231 | $15 |
| Sodium Chloride | None | 14 | $168 | $12 |
| Prednisone | None | 13 | $140 | $11 |
| Lorazepam | None | 24 | $53 | $2 |
| Carisoprodol | None | 11 | $53 | $5 |
| Clonazepam | None | 13 | $37 | $3 |
| Alprazolam | None | 12 | $16 | $1 |
Year by year
| 2024 | 2,214 | 235 | 1% (14) | None | $7,684,413 |
| 2023 | 2,371 | 225 | None | 27% | $8,721,446 |
| 2022 | 2,439 | 222 | 0% (0) | 34% | $8,192,885 |
| 2021 | 2,634 | 211 | 1% (13) | 35% | $8,536,661 |
| 2020 | 3,018 | 208 | 0% (11) | 33% | $8,903,354 |
| 2019 | 2,948 | 210 | 0% (11) | 34% | $7,696,142 |
| 2018 | 3,001 | 205 | None | 41% | $7,451,559 |
| 2017 | 2,779 | 205 | None | 46% | $7,668,496 |
| 2016 | 2,021 | 173 | None | 49% | $5,706,266 |
| 2015 | 1,396 | 112 | None | 47% | $3,400,148 |
| 2014 | 1,285 | 82 | 2% (23) | 50% | $2,700,384 |
| 2013 | 1,260 | 84 | 1% (18) | 48% | $2,346,416 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 49 drugs
| Gilenya | None | 107 | $1,366,585 | $12,772 |
| Fingolimod | None | 152 | $851,384 | $5,601 |
| Aubagio | None | 48 | $752,400 | $15,675 |
| Kesimpta | None | 47 | $735,980 | $15,659 |
| Copaxone | None | 84 | $731,720 | $8,711 |
| Tecfidera | None | 63 | $684,930 | $10,872 |
| Gammagard Liquid | Immune globulin | 37 | $437,693 | $11,830 |
| Vumerity | None | 34 | $363,068 | $10,678 |
| Mayzent | None | 16 | $359,695 | $22,481 |
| Betaseron | None | 28 | $354,610 | $12,665 |
| Gamunex-C | Immune globulin | 38 | $324,888 | $8,550 |
| Glatiramer Acetate | None | 80 | $319,472 | $3,993 |
| Dimethyl | None | 40 | $290,618 | $7,265 |
| Teriflunomide | None | 31 | $179,374 | $5,786 |
| Dalfampridine Er | None | 161 | $162,605 | $1,010 |
| Bafiertam | None | 22 | $139,630 | $6,347 |
| Ampyra | None | 13 | $96,168 | $7,398 |
| Glatopa | None | 13 | $64,989 | $4,999 |
| Modafinil | None | 136 | $20,236 | $149 |
| Lacosamide | None | 28 | $19,111 | $683 |
| Emgality | Migraine | 17 | $16,027 | $943 |
| Baclofen | None | 205 | $11,876 | $58 |
| Levetiracetam | None | 65 | $5,762 | $89 |
| Gabapentin | None | 107 | $5,538 | $52 |
| Pregabalin | None | 44 | $4,263 | $97 |
| Dextroamphetamine-Amphet Er | None | 24 | $2,175 | $91 |
| Carbamazepine | None | 15 | $1,847 | $123 |
| Armodafinil | None | 30 | $1,659 | $55 |
| Tizanidine | None | 30 | $1,535 | $51 |
| Amitriptyline | None | 35 | $1,388 | $40 |
| Mycophenolate Mofetil | None | 20 | $1,280 | $64 |
| Topiramate | None | 28 | $1,255 | $45 |
| Duloxetine | None | 42 | $1,131 | $27 |
| Divalproex Sodium Er | None | 16 | $963 | $60 |
| Sumatriptan | None | 24 | $909 | $38 |
| Dextroamphetamine-Amphetamine | None | 19 | $828 | $44 |
| Diazepam | None | 56 | $615 | $11 |
| Oxybutynin Chloride | None | 14 | $575 | $41 |
| Omeprazole | None | 18 | $316 | $18 |
| Sertraline | None | 13 | $258 | $20 |
| Clonazepam | None | 25 | $226 | $9 |
| Acyclovir | None | 15 | $201 | $13 |
| Carisoprodol | None | 11 | $197 | $18 |
| Lorazepam | None | 20 | $185 | $9 |
| Venlafaxine Hcl Er | None | 25 | $170 | $7 |
| Sodium Chloride | None | 13 | $129 | $10 |
| Amantadine | None | 11 | $126 | $11 |
| Zolpidem | None | 12 | $13 | $1 |
| Single Use Swab | None | 12 | $8 | $1 |
2022: 46 drugs
| Gilenya | None | 264 | $2,688,125 | $10,182 |
| Aubagio | None | 90 | $1,090,321 | $12,115 |
| Copaxone | None | 84 | $633,871 | $7,546 |
| Tecfidera | None | 47 | $484,542 | $10,309 |
| Gammagard Liquid | Immune globulin | 28 | $362,168 | $12,935 |
| Kesimpta | None | 29 | $294,858 | $10,168 |
| Dimethyl | None | 77 | $282,954 | $3,675 |
| Glatiramer Acetate | None | 76 | $282,338 | $3,715 |
| Betaseron | None | 28 | $282,224 | $10,079 |
| Vumerity | None | 37 | $279,838 | $7,563 |
| Mayzent | None | 28 | $268,697 | $9,596 |
| Gamunex-C | Immune globulin | 23 | $154,990 | $6,739 |
| Avonex | None | 18 | $141,453 | $7,859 |
| Dalfampridine Er | None | 224 | $111,134 | $496 |
| Fingolimod | None | 18 | $94,933 | $5,274 |
| Ampyra | None | 21 | $81,202 | $3,867 |
| Bafiertam | None | 14 | $74,096 | $5,293 |
| Modafinil | None | 113 | $41,571 | $368 |
| Glatopa | None | 11 | $18,958 | $1,723 |
| Vimpat | None | 18 | $18,140 | $1,008 |
| Baclofen | None | 207 | $14,161 | $68 |
| Ajovy | None | 12 | $8,780 | $732 |
| Lacosamide | None | 15 | $8,248 | $550 |
| Duloxetine | None | 54 | $5,990 | $111 |
| Gabapentin | None | 128 | $5,973 | $47 |
| Levetiracetam | None | 58 | $5,772 | $100 |
| Pregabalin | None | 56 | $4,195 | $75 |
| Dextroamphetamine-Amphet Er | None | 27 | $2,578 | $95 |
| Mycophenolate Mofetil | None | 19 | $1,708 | $90 |
| Armodafinil | None | 27 | $1,468 | $54 |
| Topiramate | None | 28 | $1,238 | $44 |
| Dextroamphetamine-Amphetamine | None | 17 | $1,192 | $70 |
| Amitriptyline | None | 31 | $1,187 | $38 |
| Divalproex Sodium Er | None | 16 | $976 | $61 |
| Tizanidine | None | 41 | $906 | $22 |
| Carbamazepine | None | 13 | $821 | $63 |
| Oxybutynin Chloride | None | 13 | $704 | $54 |
| Clonazepam | None | 26 | $650 | $25 |
| Acyclovir | None | 17 | $486 | $29 |
| Methylphenidate | None | 12 | $472 | $39 |
| Diazepam | None | 48 | $404 | $8 |
| Sumatriptan | None | 20 | $321 | $16 |
| Propranolol | None | 12 | $303 | $25 |
| Carisoprodol | None | 11 | $213 | $19 |
| Sertraline | None | 14 | $153 | $11 |
| Sodium Chloride | None | 13 | $132 | $10 |
2021: 45 drugs
| Gilenya | None | 314 | $3,037,113 | $9,672 |
| Aubagio | None | 102 | $944,371 | $9,259 |
| Copaxone | None | 126 | $936,137 | $7,430 |
| Tecfidera | None | 102 | $894,154 | $8,766 |
| Gammagard Liquid | Immune globulin | 22 | $382,860 | $17,403 |
| Glatiramer Acetate | None | 91 | $351,084 | $3,858 |
| Betaseron | None | 24 | $219,220 | $9,134 |
| Dimethyl | None | 65 | $203,850 | $3,136 |
| Vumerity | None | 27 | $201,128 | $7,449 |
| Avonex | None | 23 | $176,450 | $7,672 |
| Ampyra | None | 36 | $139,697 | $3,880 |
| Kesimpta | None | 18 | $134,048 | $7,447 |
| Dalfampridine Er | None | 216 | $110,570 | $512 |
| Gamunex-C | Immune globulin | 12 | $100,685 | $8,390 |
| Mayzent | None | 11 | $89,193 | $8,108 |
| Vimpat | None | 26 | $27,121 | $1,043 |
| Modafinil | None | 116 | $23,450 | $202 |
| Nuvigil | None | 11 | $12,208 | $1,110 |
| Baclofen | None | 223 | $10,012 | $45 |
| Gabapentin | None | 161 | $5,281 | $33 |
| Levetiracetam | None | 36 | $4,127 | $115 |
| Dextroamphetamine-Amphet Er | None | 28 | $3,220 | $115 |
| Pregabalin | None | 43 | $2,559 | $60 |
| Armodafinil | None | 25 | $2,371 | $95 |
| Amitriptyline | None | 59 | $1,780 | $30 |
| Duloxetine | None | 46 | $1,693 | $37 |
| Amantadine | None | 24 | $1,521 | $63 |
| Divalproex Sodium Er | None | 16 | $1,417 | $89 |
| Mycophenolate Mofetil | None | 13 | $1,358 | $104 |
| Oxybutynin Chloride | None | 30 | $1,320 | $44 |
| Dextroamphetamine-Amphetamine | None | 13 | $1,080 | $83 |
| Ropinirole | None | 15 | $988 | $66 |
| Topiramate | None | 23 | $795 | $35 |
| Diazepam | None | 72 | $670 | $9 |
| Tizanidine | None | 27 | $658 | $24 |
| Clonazepam | None | 29 | $579 | $20 |
| Cyclobenzaprine | None | 23 | $555 | $24 |
| Methylphenidate | None | 14 | $438 | $31 |
| Acyclovir | None | 17 | $335 | $20 |
| Sertraline | None | 18 | $331 | $18 |
| Sumatriptan | None | 36 | $314 | $9 |
| Carisoprodol | None | 11 | $155 | $14 |
| Ibuprofen | None | 12 | $144 | $12 |
| Citalopram Hbr | None | 16 | $60 | $4 |
| Tramadol | None | 13 | $23 | $2 |
2020: 49 drugs
| Gilenya | None | 306 | $2,941,653 | $9,613 |
| Tecfidera | None | 167 | $1,668,572 | $9,991 |
| Copaxone | None | 159 | $1,104,664 | $6,948 |
| Aubagio | None | 101 | $861,504 | $8,530 |
| Gammagard Liquid | Immune globulin | 25 | $441,171 | $17,647 |
| Glatiramer Acetate | None | 86 | $377,117 | $4,385 |
| Dalfampridine Er | None | 256 | $157,313 | $615 |
| Avonex | None | 21 | $154,257 | $7,346 |
| Ampyra | None | 35 | $108,960 | $3,113 |
| Betaseron | None | 14 | $98,519 | $7,037 |
| Gamunex-C | Immune globulin | 11 | $76,981 | $6,998 |
| Dimethyl | None | 12 | $61,521 | $5,127 |
| Vimpat | None | 36 | $34,430 | $956 |
| Modafinil | None | 162 | $23,159 | $143 |
| Baclofen | None | 300 | $13,242 | $44 |
| Aimovig | Migraine | 13 | $10,173 | $783 |
| Gabapentin | None | 208 | $6,296 | $30 |
| Lamotrigine Er | None | 11 | $4,634 | $421 |
| Dronabinol | None | 11 | $3,766 | $342 |
| Levetiracetam | None | 48 | $3,717 | $77 |
| Armodafinil | None | 33 | $3,635 | $110 |
| Mycophenolate Mofetil | None | 13 | $3,500 | $269 |
| Methylprednisolone Sodium Succ | None | 24 | $2,299 | $96 |
| Amantadine | None | 33 | $2,007 | $61 |
| Oxybutynin Chloride Er | None | 27 | $1,698 | $63 |
| Divalproex Sodium Er | None | 16 | $1,592 | $100 |
| Diclofenac | None | 17 | $1,558 | $92 |
| Amitriptyline | None | 51 | $1,540 | $30 |
| Oxybutynin Chloride | None | 40 | $1,339 | $33 |
| Ropinirole | None | 27 | $1,220 | $45 |
| Clonazepam | None | 39 | $1,193 | $31 |
| Duloxetine | None | 41 | $1,179 | $29 |
| Carbamazepine | None | 14 | $1,149 | $82 |
| Pregabalin | None | 17 | $1,082 | $64 |
| Entecavir | None | 12 | $951 | $79 |
| Dextroamphetamine-Amphetamine | None | 27 | $848 | $31 |
| Tizanidine | None | 35 | $730 | $21 |
| Topiramate | None | 23 | $572 | $25 |
| Cyclobenzaprine | None | 41 | $572 | $14 |
| Diazepam | None | 71 | $469 | $7 |
| Quetiapine | None | 18 | $408 | $23 |
| Sertraline | None | 19 | $345 | $18 |
| Sumatriptan | None | 30 | $271 | $9 |
| Paroxetine | None | 14 | $245 | $18 |
| Rizatriptan | None | 11 | $223 | $20 |
| Methylphenidate | None | 12 | $189 | $16 |
| Trazodone | None | 12 | $103 | $9 |
| Buspirone | None | 13 | $88 | $7 |
| Benztropine Mesylate | None | 12 | $44 | $4 |
2019: 50 drugs
| Gilenya | None | 329 | $2,807,274 | $8,533 |
| Tecfidera | None | 143 | $1,305,804 | $9,131 |
| Copaxone | None | 194 | $1,305,154 | $6,728 |
| Aubagio | None | 85 | $646,075 | $7,601 |
| Gammagard Liquid | Immune globulin | 20 | $336,782 | $16,839 |
| Dalfampridine Er | None | 253 | $244,467 | $966 |
| Glatiramer Acetate | None | 58 | $232,299 | $4,005 |
| Betaseron | None | 22 | $162,444 | $7,384 |
| Ampyra | None | 54 | $154,608 | $2,863 |
| Rebif | None | 11 | $85,937 | $7,812 |
| Gamunex-C | Immune globulin | 12 | $82,855 | $6,905 |
| Vimpat | None | 25 | $23,666 | $947 |
| Nuvigil | None | 12 | $20,063 | $1,672 |
| Modafinil | None | 118 | $16,251 | $138 |
| Lyrica | None | 18 | $11,707 | $650 |
| Baclofen | None | 287 | $9,458 | $33 |
| Vesicare | None | 13 | $8,664 | $666 |
| Gabapentin | None | 217 | $6,449 | $30 |
| Mycophenolate Mofetil | None | 21 | $5,187 | $247 |
| Armodafinil | None | 29 | $3,114 | $107 |
| Carbamazepine Er | None | 20 | $3,006 | $150 |
| Amantadine | None | 35 | $2,466 | $70 |
| Duloxetine | None | 46 | $2,291 | $50 |
| Methylprednisolone Sodium Succ | None | 25 | $2,159 | $86 |
| Oxybutynin Chloride | None | 37 | $1,965 | $53 |
| Oxybutynin Chloride Er | None | 23 | $1,731 | $75 |
| Carbamazepine | None | 31 | $1,641 | $53 |
| Levetiracetam | None | 52 | $1,480 | $28 |
| Amitriptyline | None | 51 | $1,158 | $23 |
| Tizanidine | None | 41 | $1,145 | $28 |
| Topiramate | None | 39 | $1,118 | $29 |
| Divalproex Sodium Er | None | 16 | $979 | $61 |
| Entecavir | None | 12 | $947 | $79 |
| Clonazepam | None | 44 | $849 | $19 |
| Ropinirole | None | 14 | $722 | $52 |
| Sumatriptan | None | 46 | $581 | $13 |
| Dextroamphetamine-Amphetamine | None | 13 | $431 | $33 |
| Diazepam | None | 55 | $421 | $8 |
| Escitalopram | None | 11 | $392 | $36 |
| Quetiapine | None | 18 | $358 | $20 |
| Sertraline | None | 31 | $320 | $10 |
| Omeprazole | None | 11 | $256 | $23 |
| Zolpidem | None | 12 | $176 | $15 |
| Ibuprofen | None | 12 | $170 | $14 |
| Prednisone | None | 15 | $157 | $10 |
| Paroxetine | None | 13 | $130 | $10 |
| Trazodone | None | 13 | $124 | $10 |
| Buspirone | None | 12 | $102 | $9 |
| Citalopram Hbr | None | 16 | $76 | $5 |
| Benztropine Mesylate | None | 20 | $59 | $3 |
2018: 52 drugs
| Gilenya | None | 325 | $2,718,239 | $8,364 |
| Copaxone | None | 188 | $1,269,215 | $6,751 |
| Tecfidera | None | 118 | $1,040,896 | $8,821 |
| Ampyra | None | 269 | $743,831 | $2,765 |
| Aubagio | None | 98 | $650,474 | $6,637 |
| Gammagard Liquid | Immune globulin | 15 | $226,829 | $15,122 |
| Betaseron | None | 19 | $158,095 | $8,321 |
| Glatiramer Acetate | None | 25 | $103,940 | $4,158 |
| Gamunex-C | Immune globulin | 14 | $91,854 | $6,561 |
| Avonex | None | 13 | $85,781 | $6,599 |
| Dalfampridine Er | None | 43 | $59,639 | $1,387 |
| Vimpat | None | 21 | $22,197 | $1,057 |
| Modafinil | None | 96 | $21,616 | $225 |
| Lyrica | None | 27 | $12,570 | $466 |
| Vesicare | None | 15 | $10,962 | $731 |
| Baclofen | None | 294 | $8,069 | $27 |
| Mycophenolate Mofetil | None | 40 | $6,499 | $162 |
| Gabapentin | None | 211 | $4,530 | $21 |
| Amantadine | None | 38 | $4,483 | $118 |
| Nuvigil | None | 12 | $3,734 | $311 |
| Carbamazepine Er | None | 20 | $2,902 | $145 |
| Carbamazepine | None | 33 | $2,224 | $67 |
| Duloxetine | None | 31 | $2,185 | $70 |
| Oxybutynin Chloride | None | 38 | $2,046 | $54 |
| Oxybutynin Chloride Er | None | 38 | $1,950 | $51 |
| Armodafinil | None | 22 | $1,898 | $86 |
| Ropinirole | None | 18 | $1,872 | $104 |
| Clonazepam | None | 44 | $1,181 | $27 |
| Dextroamphetamine-Amphet Er | None | 11 | $1,123 | $102 |
| Levetiracetam | None | 68 | $989 | $15 |
| Divalproex Sodium Er | None | 14 | $961 | $69 |
| Amitriptyline | None | 74 | $957 | $13 |
| Tizanidine | None | 45 | $885 | $20 |
| Memantine | None | 11 | $630 | $57 |
| Sumatriptan | None | 38 | $625 | $16 |
| Topiramate | None | 28 | $601 | $21 |
| Escitalopram | None | 16 | $449 | $28 |
| Prednisone | None | 18 | $365 | $20 |
| Butalbital-Acetaminophen-Caffe | None | 19 | $352 | $19 |
| Quetiapine | None | 15 | $310 | $21 |
| Acyclovir | None | 21 | $302 | $14 |
| Sertraline | None | 33 | $250 | $8 |
| Diazepam | None | 46 | $244 | $5 |
| Propranolol | None | 11 | $207 | $19 |
| Ondansetron Odt | None | 19 | $206 | $11 |
| Phenytoin Sodium Extended | None | 12 | $174 | $15 |
| Zolpidem | None | 13 | $136 | $10 |
| Omeprazole | None | 13 | $122 | $9 |
| Divalproex | None | 11 | $118 | $11 |
| Paroxetine | None | 14 | $111 | $8 |
| Naproxen | None | 14 | $104 | $7 |
| Citalopram Hbr | None | 11 | $31 | $3 |
2017: 55 drugs
| Gilenya | None | 405 | $3,136,089 | $7,743 |
| Tecfidera | None | 175 | $1,355,774 | $7,747 |
| Copaxone | None | 182 | $1,354,297 | $7,441 |
| Ampyra | None | 219 | $538,257 | $2,458 |
| Aubagio | None | 65 | $393,700 | $6,057 |
| Betaseron | None | 24 | $200,441 | $8,352 |
| Glatopa | None | 21 | $110,041 | $5,240 |
| Plegridy | None | 14 | $91,384 | $6,527 |
| Avonex | None | 11 | $70,699 | $6,427 |
| Gamunex-C | Immune globulin | 11 | $69,847 | $6,350 |
| Modafinil | None | 76 | $19,155 | $252 |
| Vimpat | None | 18 | $14,474 | $804 |
| Vesicare | None | 14 | $8,125 | $580 |
| Mycophenolate Mofetil | None | 29 | $6,302 | $217 |
| Nuvigil | None | 11 | $5,920 | $538 |
| Baclofen | None | 196 | $5,825 | $30 |
| Lyrica | None | 17 | $5,568 | $328 |
| Amantadine | None | 37 | $3,887 | $105 |
| Gabapentin | None | 193 | $3,628 | $19 |
| Carbamazepine Er | None | 16 | $2,322 | $145 |
| Oxybutynin Chloride Er | None | 33 | $2,035 | $62 |
| Ropinirole | None | 13 | $2,011 | $155 |
| Divalproex Sodium Er | None | 16 | $1,999 | $125 |
| Oxybutynin Chloride | None | 31 | $1,737 | $56 |
| Methylprednisolone Sodium Succ | None | 24 | $1,293 | $54 |
| Memantine | None | 13 | $956 | $74 |
| Nitrofurantoin | None | 24 | $919 | $38 |
| Levetiracetam | None | 43 | $738 | $17 |
| Phenytoin Sodium Extended | None | 42 | $658 | $16 |
| Tizanidine | None | 53 | $620 | $12 |
| Amitriptyline | None | 47 | $565 | $12 |
| Sumatriptan | None | 38 | $557 | $15 |
| Clonazepam | None | 34 | $556 | $16 |
| Prednisone | None | 27 | $514 | $19 |
| Duloxetine | None | 19 | $508 | $27 |
| Valacyclovir | None | 14 | $451 | $32 |
| Escitalopram | None | 20 | $435 | $22 |
| Diazepam | None | 39 | $273 | $7 |
| Divalproex | None | 36 | $268 | $7 |
| Topiramate | None | 23 | $241 | $10 |
| Rizatriptan | None | 11 | $232 | $21 |
| Verapamil Er | None | 15 | $191 | $13 |
| Levothyroxine | None | 12 | $191 | $16 |
| Sulfamethoxazole-Trimethoprim | None | 14 | $162 | $12 |
| Ibuprofen | None | 21 | $159 | $8 |
| Fluoxetine | None | 12 | $156 | $13 |
| Sertraline | None | 17 | $143 | $8 |
| Acyclovir | None | 16 | $120 | $7 |
| Citalopram Hbr | None | 26 | $106 | $4 |
| Paroxetine | None | 13 | $89 | $7 |
| Naproxen | None | 12 | $86 | $7 |
| Zolpidem | None | 13 | $56 | $4 |
| Cyclobenzaprine | None | 12 | $54 | $4 |
| Hydroxyzine | None | 11 | $38 | $3 |
| Lorazepam | None | 13 | $14 | $1 |
2016: 41 drugs
| Gilenya | 341 | $2,472,926 | $7,252 |
| Tecfidera | 148 | $1,068,093 | $7,217 |
| Copaxone | 142 | $965,584 | $6,800 |
| Ampyra | 118 | $278,756 | $2,362 |
| Betaseron | 30 | $223,526 | $7,451 |
| Aubagio | 31 | $179,365 | $5,786 |
| Plegridy | 12 | $71,374 | $5,948 |
| Avonex | 11 | $63,850 | $5,805 |
| Glatopa | 11 | $60,254 | $5,478 |
| Nuvigil | 34 | $24,203 | $712 |
| Modafinil | 67 | $17,565 | $262 |
| Vimpat | 14 | $13,040 | $931 |
| Namenda Xr | 12 | $4,278 | $357 |
| Baclofen | 129 | $4,046 | $31 |
| Divalproex Sodium Er | 22 | $2,669 | $121 |
| Gabapentin | 134 | $2,626 | $20 |
| Amantadine | 31 | $2,414 | $78 |
| Carbamazepine Er | 17 | $2,269 | $133 |
| Carbamazepine | 15 | $1,679 | $112 |
| Mycophenolate Mofetil | 22 | $1,644 | $75 |
| Oxybutynin Chloride Er | 15 | $1,378 | $92 |
| Methylprednisolone Sod Succ | 19 | $1,012 | $53 |
| Oxybutynin Chloride | 24 | $927 | $39 |
| Memantine | 11 | $827 | $75 |
| Clonazepam | 14 | $605 | $43 |
| Donepezil | 25 | $493 | $20 |
| Sumatriptan | 37 | $429 | $12 |
| Escitalopram | 17 | $377 | $22 |
| Amitriptyline | 37 | $335 | $9 |
| Rizatriptan | 13 | $297 | $23 |
| Duloxetine | 12 | $296 | $25 |
| Levetiracetam | 12 | $248 | $21 |
| Tizanidine | 19 | $233 | $12 |
| Prednisone | 12 | $226 | $19 |
| Ibuprofen | 25 | $151 | $6 |
| Acyclovir | 16 | $150 | $9 |
| Cyclobenzaprine | 15 | $81 | $5 |
| Paroxetine | 13 | $80 | $6 |
| Sertraline | 13 | $73 | $6 |
| Citalopram Hbr | 13 | $60 | $5 |
| Zolpidem | 18 | $31 | $2 |
2015: 31 drugs
| Gilenya | 192 | $1,195,816 | $6,228 |
| Tecfidera | 97 | $625,269 | $6,446 |
| Copaxone | 93 | $615,028 | $6,613 |
| Ampyra | 103 | $204,327 | $1,984 |
| Rebif | 13 | $132,064 | $10,159 |
| Betaseron | 22 | $118,679 | $5,395 |
| Avonex | 18 | $92,732 | $5,152 |
| Aubagio | 13 | $78,867 | $6,067 |
| Nuvigil | 29 | $16,193 | $558 |
| Modafinil | 29 | $12,948 | $446 |
| Baclofen | 110 | $3,875 | $35 |
| Gabapentin | 83 | $1,900 | $23 |
| Amantadine | 18 | $1,707 | $95 |
| Divalproex Sodium Er | 18 | $1,559 | $87 |
| Carbamazepine | 11 | $1,204 | $109 |
| Methylprednisolone Sod Succ | 30 | $1,024 | $34 |
| Amitriptyline | 37 | $609 | $16 |
| Oxybutynin Chloride | 18 | $464 | $26 |
| Clonazepam | 38 | $464 | $12 |
| Sumatriptan | 22 | $383 | $17 |
| Levetiracetam | 13 | $304 | $23 |
| Nitrofurantoin | 11 | $272 | $25 |
| Tizanidine | 12 | $253 | $21 |
| Escitalopram | 15 | $223 | $15 |
| Levothyroxine | 12 | $197 | $16 |
| Donepezil | 21 | $194 | $9 |
| Ibuprofen | 19 | $120 | $6 |
| Paroxetine | 13 | $70 | $5 |
| Sertraline | 14 | $66 | $5 |
| Diazepam | 15 | $45 | $3 |
| Trazodone | 11 | $35 | $3 |
2014: 25 drugs
| Gilenya | 200 | $1,012,511 | $5,063 |
| Copaxone | 102 | $552,408 | $5,416 |
| Tecfidera | 59 | $297,004 | $5,034 |
| Ampyra | 121 | $218,219 | $1,803 |
| Avonex | 44 | $207,883 | $4,725 |
| Aubagio | 23 | $127,326 | $5,536 |
| Betaseron | 15 | $99,533 | $6,636 |
| Avonex | 13 | $62,393 | $4,799 |
| Modafinil | 26 | $19,477 | $749 |
| Nuvigil | 27 | $13,822 | $512 |
| Lyrica | 15 | $3,738 | $249 |
| Baclofen | 109 | $2,909 | $27 |
| Gabapentin | 74 | $2,410 | $33 |
| Amantadine | 11 | $1,324 | $120 |
| Methylprednisolone Sod Succ | 28 | $777 | $28 |
| Tizanidine | 11 | $457 | $42 |
| Escitalopram | 15 | $445 | $30 |
| Sumatriptan | 16 | $378 | $24 |
| Amitriptyline | 36 | $362 | $10 |
| Clonazepam | 28 | $361 | $13 |
| Phenytoin Sodium Extended | 11 | $266 | $24 |
| Hydrocodone-Acetaminophen | 20 | $212 | $11 |
| Levothyroxine | 15 | $200 | $13 |
| Ibuprofen | 17 | $138 | $8 |
| Trazodone | 12 | $31 | $3 |
2013: 32 drugs
| Gilenya | 153 | $815,317 | $5,329 |
| Copaxone | 124 | $579,946 | $4,677 |
| Ampyra | 139 | $228,106 | $1,641 |
| Betaseron | 44 | $208,089 | $4,729 |
| Rebif | 19 | $109,609 | $5,769 |
| Aubagio | 23 | $88,793 | $3,861 |
| Avonex | 19 | $81,758 | $4,303 |
| Tecfidera | 18 | $79,880 | $4,438 |
| Modafinil | 22 | $20,726 | $942 |
| Nuvigil | 29 | $12,892 | $445 |
| Gabapentin | 80 | $3,751 | $47 |
| Escitalopram | 19 | $1,890 | $99 |
| Baclofen | 104 | $1,670 | $16 |
| Amantadine | 21 | $1,558 | $74 |
| Methylprednisolone Sod Succ | 23 | $850 | $37 |
| Zonisamide | 12 | $714 | $59 |
| Clonazepam | 17 | $557 | $33 |
| Donepezil | 15 | $440 | $29 |
| Phenytoin Sodium Extended | 24 | $379 | $16 |
| Tizanidine | 12 | $362 | $30 |
| Sumatriptan | 14 | $261 | $19 |
| Oxybutynin Chloride | 12 | $242 | $20 |
| Hydrocodone-Acetaminophen | 17 | $182 | $11 |
| Amitriptyline | 52 | $171 | $3 |
| Verapamil Er | 12 | $144 | $12 |
| Omeprazole | 17 | $143 | $8 |
| Promethazine | 12 | $135 | $11 |
| Paroxetine | 11 | $129 | $12 |
| Ibuprofen | 20 | $116 | $6 |
| Diazepam | 16 | $106 | $7 |
| Sertraline | 14 | $45 | $3 |
| Carisoprodol | 11 | $42 | $4 |
Money from drug and device companies
$119 in 2024
| 2024 | 2 | 2 | None | $119 |
| 2023 | 1 | 1 | $1,300 | $1,300 |
| 2022 | 1 | 1 | None | $31 |
| 2020 | 2 | 2 | None | $147 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Kesimpta | $83 | 1 payment
|
| Alexion Pharmaceuticals | None | $36 | 1 payment
|
See all 2 published payments
| Alexion Pharmaceuticals | Meals · 2024-09-06 | None | $36 |
| Novartis Pharmaceuticals | Meals · 2024-07-24 | Kesimpta | $83 |
See earlier years (2023, 2022, 2020)
2023: $1,300
| Cycle Pharmaceuticals | Nityr | $1,300 | 1 payment
|
2022: $31
| EMD Serono | None | $31 | 1 payment
|
2020: $147
| Alexion Pharmaceuticals | Soliris | $94 | 1 payment
|
| Novartis Pharmaceuticals | Mayzent | $53 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis · 2024 | Their institution | $373,157 |
| Novartis Pharmaceuticals Corporation · An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis · 2025 | Their institution | $334,027 |
| Novartis Pharmaceuticals Corporation · An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis · 2022 | Their institution | $305,905 |
| Novartis Pharmaceuticals Corporation · An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis · 2023 | Their institution | $305,400 |
| Novartis Pharmaceuticals Corporation · An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis · 2021 | Their institution | $215,216 |
| AbbVie Inc. · 2020 | Their institution | $89,606 |
| Novartis Pharmaceuticals Corporation · An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis · 2020 | Their institution | $79,262 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod Baf312 in Patients With Secondary Progressive Multiple Sclerosis · 2021 | Their institution | $64,072 |
| Novartis Pharmaceuticals Corporation · A 12 Month Randomized Rater and Dose Blinded Study To Compare the Efficacy and Safety of Fingolimod Twenty Five Hundredth of A Mg and Half of A Mg Administered Orally Once Daily With Glatiramer Acetate 20 Mg Administered Subcutaneously Once Daily in Patie · 2019 | Their institution | $58,458 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod Baf312 in Patients With Secondary Progressive Multiple Sclerosis · 2019 | Their institution | $52,422 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod Baf312 in Patients With Secondary Progressive Multiple Sclerosis · 2020 | Their institution | $50,565 |
| Adamas Pharmaceuticals, Inc. · A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study To Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment · 2019 | Their institution | $48,212 |
| AbbVie, Inc. · 2019 | Their institution | $42,286 |
| Celgene Corporation · Phiii Efficacy and Safety of Rpc1063 in Relapsing Ms (Rpc01-3001) · 2020 | Their institution | $36,702 |
| Genentech, Inc. · Ocrelizumab Ppms High Dose Study · 2021 | Their institution | $28,872 |
| Genentech, Inc. · Ocrelizumab Rms High Dose Study · 2021 | Their institution | $27,097 |
| ABBVIE INC. · A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study To Assess the Safety and Efficacy of Elezanumab When Added To Standard of Care in Relapsing Forms of Multiple Sclerosis · 2021 | Their institution | $23,280 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis · 2019 | Their institution | $21,943 |
| Adamas Pharmaceuticals, Inc. · A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment · 2021 | Their institution | $21,645 |
| Janssen Research & Development, LLC · Multi Center Randomized Double Blind Parallel Group Extension Study Ac058b201 To Investigate the Long Term Tolerability and Efficacy of 10 20 and 40 Mg Day Act129900 and Oral S1p1 Receptor Agonist in Patients With Relapsing Remitting Multiple Sclerosis · 2021 | Their institution | $21,152 |
| Novartis Pharmaceuticals Corporation · An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis · 2019 | Their institution | $19,578 |
| Janssen Research & Development, LLC · Multi Center Randomized Double Blind Parallel Group Extension Study Ac058b201 To Investigate the Long Term Tolerability and Efficacy of 10 20 and 40 Mg Day Act129900 and Oral S1p1 Receptor Agonist in Patients With Relapsing Remitting Multiple Sclerosis · 2022 | Their institution | $18,767 |
| ABBVIE INC. · A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study To Assess the Safety and Efficacy of Elezanumab When Added To Standard of Care in Progressive Forms of Multiple Sclerosis · 2021 | Their institution | $18,660 |
| Celgene Corporation · A Multicenter, Longitudinal, Open-Label, Single-Ar · 2021 | Their institution | $16,479 |
| Janssen Research & Development, LLC · Ms Phase 2 Extension Hq - Ac-058b202 · 2019 | Their institution | $15,595 |
| Novartis Pharmaceuticals Corporation · A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis · 2020 | Their institution | $13,600 |
| Adamas Pharmaceuticals, Inc. · A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment · 2019 | Their institution | $13,032 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod Baf312 in Patients With Secondary Progressive Multiple Sclerosis · 2022 | Their institution | $12,798 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2021 | Their institution | $12,765 |
| Janssen Research & Development, LLC · Multicenter, Randomized, Double-Blind, Parallel-Group Extension Study Ac-058b201 To Investigate the Long-Term, Tolerability, and Efficacy of 10, 20, and 40 Mg/Day Act-129900, and Oral S1p1 Receptor Agonist, in Patients With Relapsing-Remitting Multiple Sclerosis · 2020 | Their institution | $11,878 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2020 | Their institution | $10,650 |
| Adamas Pharmaceuticals, Inc. · A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study To Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment · 2020 | Their institution | $10,471 |
| Novartis Pharmaceuticals Corporation · A 12 Month Prospective Multicenter Two Cohort Nonrandomized Open Label Study in Adult Patients With Relapsing Multiple Sclerosis Rms To Investigate Changes in Immune Phenotype Biomarkers After Treatment With 05mg Fingolimod Fluent · 2019 | Their institution | $10,382 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2022 | Their institution | $8,995 |
| Adamas Pharmaceuticals, Inc. · A Multicenter Open-Label Safety and Efficacy Study of Ads-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment · 2020 | Their institution | $8,534 |
| Genentech, Inc. · Ocrelizumab Rms High Dose Study · 2022 | Their institution | $7,005 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2023 | Their institution | $6,728 |
| ABBVIE INC. · A Study To Assess the Safety and Efficacy of Elezanumab When Added To Standard of Care in Progressive Forms of Multiple Sclerosis · 2021 | Their institution | $6,441 |
| Genentech, Inc. · Ocrelizumab Ppms High Dose Study · 2022 | Their institution | $6,375 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2025 | Their institution | $6,250 |
| ABBVIE INC. · A Study To Assess the Safety and Efficacy of Elezanumab When Added To Standard of Care in Relapsing Forms of Multiple Sclerosis · 2021 | Their institution | $5,658 |
| Celgene Corporation · A Multicenter, Longitudinal, Open-Label, Single-Ar - A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (Rpc-1063) · 2022 | Their institution | $4,130 |
| Roche Products Limited · Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment · 2024 | Their institution | $3,534 |
| Celgene Corporation · A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (Rpc-1063) (Bms Study Number: Im047-P46) · 2020 | Their institution | $3,400 |
| Celgene Corporation · Phiii Efficacy and Safety of Rpc1063 in Relapsing Ms (Rpc01-3001) (Rpc01-3001) · 2019 | Their institution | $2,692 |
| Novartis Pharmaceuticals Corporation · A 12 Month Prospective Multicenter Two Cohort Nonrandomized Open Label Study in Adult Patients With Relapsing Multiple Sclerosis Rms To Investigate Changes in Immune Phenotype Biomarkers After Treatment With 05mg Fingolimod Fluent · 2021 | Their institution | $1,600 |
| AstraZeneca Pharmaceuticals LP · A Double Masked Placebo Controlled Study With Open Label Period To Evaluate the Efficacy and Safety of Medi551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders · 2020 | Their institution | $289 |
Professional record
- NPI
- 1568400265
- Licence
- CA A82317California A82317: Current · expires 2028-09-30
- Trained
- University of Hawaii John A. Burns School of Medicine, 2001 · 25 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 4860 Y St, Department of Neurology, Suite 3700, Sacramento, CA, 95817
- NPI first listed
- 2006-06-03
- NPI last updated
- 2026-07-13
This is when the NPI record was last certified, not a medical board exam.